AMPE.US
id: 111
Ampio (AMPE) $3M Shareholder Settlement
Eligible claimants can submit their claims for compensation.
D. Colorado
Court1:22-cv-02105
Case number12/29/2020
Class period Start10/31/2022
Class period End01/13/2025
Claim deadlineAmpio (AMPE) agreed to settle $3M with investors to end claims over misrepresenting the efficacy of Ampion in treating individuals with inflammatory conditions.
Case Details:
In 2022, Ampio (AMPE) issued a letter to Shareholders covering the initial results of the investigation initiated on May 16, 2022.
- Special Committee's primary findings include that certain former Ampio executive officers and senior staff were aware, at the time of the per-protocol interim analysis in March 2020, that the AP-013 trial did not demonstrate efficacy for Ampion on its co-primary endpoints of pain and function;
- These former Ampio executive officers and senior staff did not fully report the results of the AP-013 trial and the timing of unblinding of data from the AP-013 trial.
Case Status
Accepting Claims
Alleged Offence
Misleading Statements,
Financial Misrepresentation,
Failure to Disclose,
Omissions
Suspected Party
Directors,
Management
Security Type
Stocks
Trade Direction
Long
Payout per Share
0.15
Filing date
08/17/2022
Lead Plaintiff Deadline
10/17/2022
Plaintiffs
Tao Wang, Christopher Kain
Attorneys
Faruqi & Faruqi LLP (New York, NY)
Defendants
Michael A. Martino, Michael Macaluso, Holli Cherevka, Dan Stokely, David Bar-Or, Philip H. Coelho, Richard B. Giles
Judge
Hon. William J. Martinez
Administrator
Strategic Claims Services
Settlement agreement date
2024-05-13
Court hearing date
02/19/2025
Exclusion deadline
01/29/2025
Objection deadline
09/10/2024
Hearing deadline
10/15/2024
Attorney fee
$915,000
Trades matching type
FIFO
+$3,000,000
Cash Settlement Amount